SAN DIEGO--(BUSINESS WIRE)--Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) has received a ‘Notice of Allowance’ on a US patent application from the United States Patent and Trademark Office protecting its lead drug candidate, OPT-80, which is being developed for the treatment of Clostridium difficile infection, or CDI. The pending patent covers the polymorphic form of the active pharmaceutical ingredient and once issued, will offer patent protection through 2025.
